#Ireland #Dublin #Mallinckrodt #Acthar Gel #Keenova Therapeutics

Mallinckrodt's Financial Performance: Q3 2025 Overview

Mallinckrodt plc recently unveiled its financial results for the third quarter of 2025, showcasing a remarkable growth trajectory with net sales reaching $753.1 million. This represents an impressive 49% increase from the $505.5 million reported in the same quarter last year. This growth is attributed to the robust performance of Acthar® Gel, a repository corticotropin injection, and the positive impact of the merger with Endo, Inc. This merger not only accelerated product sales but also broadened the company’s therapeutic portfolio. As of July 31, 2025, after completing the merger, Mallinckrodt transitioned to a new brand, Keenova Therapeutics, focusing solely on branded therapeutics.

Key Financial Highlights

The third quarter results reflected a significant boost in sales across different segments. The Specialty Brands segment, which now encompasses both Mallinckrodt's historical and Endo's branded pharmaceuticals, achieved net sales of $416 million—marked by a 45.5% increase from the $286 million reported in Q3 2024. Notably, Acthar Gel sales rose by 43.5%, generating $181.4 million. The merger additionally introduced XIAFLEX® sales amounting to $90.1 million to the financials. Conversely, the Generics and Sterile Injectables segment also registered strong performance with $337.1 million in sales, reflecting a 53.6% increase compared to the previous year.

Despite these soaring sales figures, the company reported a net loss of $291.1 million in Q3, a stark increase from a net loss of $26.2 million in the same period last year. This loss was primarily driven by merger-related costs, including compensation expenses exceeding $123 million and cash costs approximating $93.8 million associated with the transition and separation of Par Health, the spin-off entity comprising generics and sterile injectable products. Additionally, significant non-cash expenses related to inventory and intangible asset adjustments contributed to the net loss.

Future Outlook

Looking ahead, Mallinckrodt has adjusted its full-year guidance for Acthar Gel sales growth to anticipate an increase between 30% to 35%, up from an earlier forecast of 20% to 30%. They expect fourth-quarter net sales to fall within the range of $485 million to $505 million, alongside adjusted EBITDA estimates of $155 million to $165 million. This optimistic forecast signifies a strong belief in the ongoing demand for Acthar Gel and the potential of the newly combined therapeutic offerings following the Endo merger.

The CEO of Mallinckrodt, Siggi Olafsson, expressed enthusiasm regarding the company's trajectory, stating, "We are excited to begin our next chapter as Keenova Therapeutics, a pure-play branded therapeutics company focused on addressing unmet patient needs." The leadership is strongly focused on leveraging resources and momentum to enhance patient benefits and drive shareholder value.

Strategic Enhancements Post-Merger

The merger and subsequent spin-off of its generic and injectable businesses under Par Health have allowed Mallinckrodt to sharpen its focus on branded therapeutic development. With a consolidated structure, Keenova aims to harness synergies and efficiencies, projecting pre-tax run-rate synergies in excess of $75 million within the next year, with a goal of reaching approximately $150 million within three years.

This strategic consolidation is designed to drive operational efficiencies and enhance the company’s market position significantly over the coming years. Furthermore, Mallinckrodt plans to continue investing in its production capabilities and expanding its pipeline to address a broad spectrum of therapeutic areas.

Conclusion

Mallinckrodt's Q3 2025 results demonstrate a marked improvement following the Endo acquisition and the establishment of Keenova Therapeutics. Although the company faces short-term losses attributable to merger integration costs, the long-term outlook appears promising with notable sales growth and strategic focus on meeting rare and unmet medical needs. Investors will be keen to watch how these changes unfold and drive the company’s growth in the near future.